These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28639315)

  • 41. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
    Oh EJ; Yang WI; Cheong JW; Choi SE; Yoon SO
    Hum Pathol; 2014 Oct; 45(10):2043-50. PubMed ID: 25149548
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin.
    Rink JS; Yang S; Cen O; Taxter T; McMahon KM; Misener S; Behdad A; Longnecker R; Gordon LI; Thaxton CS
    Mol Pharm; 2017 Nov; 14(11):4042-4051. PubMed ID: 28933554
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TCL1 as a hub protein associated with the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma based on proteomics methods.
    Gao HX; Li SJ; Niu J; Ma ZP; Nuerlan A; Xue J; Wang MB; Cui WL; Abulajiang G; Sang W; Zhang W; Li XX
    Pathol Res Pract; 2020 Feb; 216(2):152799. PubMed ID: 31932115
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
    Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Aggressive B-cell lymphomas of gastrointestinal tract: a clinicopathologic analysis of 54 cases].
    Zhou J; Xia C; Shen Q; Yin H; Zhang X; Shi Q; Zhou X; Ma J
    Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):8-14. PubMed ID: 24713242
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system.
    Tapia G; Baptista MJ; Muñoz-Marmol AM; Gaafar A; Puente-Pomposo M; Garcia O; Marginet-Flinch R; Sanz C; Navarro JT; Sancho JM; Ribera JM; Ariza A; Mate JL
    APMIS; 2015 Jul; 123(7):596-603. PubMed ID: 26010683
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BCR signals target p27(Kip1) and cyclin D2 via the PI3-K signalling pathway to mediate cell cycle arrest and apoptosis of WEHI 231 B cells.
    Banerji L; Glassford J; Lea NC; Thomas NS; Klaus GG; Lam EW
    Oncogene; 2001 Nov; 20(50):7352-67. PubMed ID: 11704865
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD
    Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens.
    Young RM; Wu T; Schmitz R; Dawood M; Xiao W; Phelan JD; Xu W; Menard L; Meffre E; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Staudt LM
    Proc Natl Acad Sci U S A; 2015 Nov; 112(44):13447-54. PubMed ID: 26483459
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients.
    Abdulla M; Laszlo S; Triumf J; Hedström G; Berglund M; Enblad G; Amini RM
    Acta Oncol; 2016; 55(9-10):1126-1131. PubMed ID: 27549735
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.
    Akhter A; Masir N; Elyamany G; Phang KC; Mahe E; Al-Zahrani AM; Shabani-Rad MT; Stewart DA; Mansoor A
    J Neurooncol; 2015 Jan; 121(2):289-96. PubMed ID: 25391967
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma.
    Schuhmacher B; Rengstl B; Döring C; Bein J; Newrzela S; Brunnberg U; Kvasnicka HM; Vornanen M; Küppers R; Hansmann ML; Hartmann S
    Oncotarget; 2016 Nov; 7(44):72197-72210. PubMed ID: 27708232
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel synthetic 4-chlorobenzoyl berbamine inhibits c-Myc expression and induces apoptosis of diffuse large B cell lymphoma cells.
    Zhang L; Tong J; He X; Liang Y; Zhu L; Xu R; Zhao X
    Ann Hematol; 2018 Dec; 97(12):2353-2362. PubMed ID: 30099568
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.
    Lyu MA; Sung B; Cheung LH; Marks JW; Aggarwal BB; Aguiar RC; Rosenblum MG
    Biochem Pharmacol; 2010 Nov; 80(9):1335-42. PubMed ID: 20654581
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Significance of myc gene rearrangement and its correlation with prognosis in diffuse large B cell lymphoma].
    Zhang HW; Chen ZW; He JX; Zheng YP; Han WE; Zhao ZQ; Bai W; Wang JF
    Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):119-23. PubMed ID: 23714666
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MiR-17-92 represses PTPROt and PP2A phosphatases and amplifies tonic BCR signaling in DLBCL cells.
    Jablonska E; Gorniak P; Szydlowski M; Sewastianik T; Bialopiotrowicz E; Polak A; Warzocha K; Juszczynski P
    Exp Hematol; 2017 Feb; 46():56-61.e1. PubMed ID: 27720936
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.
    Dworakowska D; Wlodek E; Leontiou CA; Igreja S; Cakir M; Teng M; Prodromou N; Góth MI; Grozinsky-Glasberg S; Gueorguiev M; Kola B; Korbonits M; Grossman AB
    Endocr Relat Cancer; 2009 Dec; 16(4):1329-38. PubMed ID: 19620247
    [TBL] [Abstract][Full Text] [Related]  

  • 59. AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.
    Devlin JR; Hannan KM; Ng PY; Bywater MJ; Shortt J; Cullinane C; McArthur GA; Johnstone RW; Hannan RD; Pearson RB
    FEBS J; 2013 Nov; 280(21):5307-16. PubMed ID: 23331925
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
    Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.